期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
A novel oncolytic virus engineered with PD-L1 scFv effectively inhibits tumor growth in a mouse model 被引量:4
1
作者 Chuanjian Wu Manman Wu +2 位作者 minglong liang Sidong Xiong Chunsheng Dong 《Cellular & Molecular Immunology》 SCIE CAS CSCD 2019年第9期780-782,共3页
The adoptive transfer of engineered chimeric antigen receptor(CAR)T cells has yielded impressive clinical results for targeting hematological cancers.1 However,the advancement of CAR T-cell therapy in solid tumors rem... The adoptive transfer of engineered chimeric antigen receptor(CAR)T cells has yielded impressive clinical results for targeting hematological cancers.1 However,the advancement of CAR T-cell therapy in solid tumors remains limited,due to the scarcity of tumor antigens that are deemed safe for targeting.Moreover,the requirement of patient-specific autologous T cells for the current standard treatment has also hampered its application.Oncolytic virus(OV)therapy has been classified as another form of novel immunotherapy. 展开更多
关键词 THERAPY CLINICAL engineered
原文传递
A single dose of recombinant VSV-RABVG vaccine provides full protection against RABV challenge
2
作者 minglong liang Zongmei Wang +3 位作者 Chuanjian Wu Sidong Xiong Ling Zhao Chunsheng Dong 《Virologica Sinica》 SCIE CAS CSCD 2022年第3期455-458,共4页
Dear Editor,Rabies virus(RABV)is an enveloped,non-segmented,and singlestranded RNA virus that belongs to the genus Lyssavirus within the Rhabdoviridae family(Douglas et al.,2013).RABV causes rabies,and although vaccin... Dear Editor,Rabies virus(RABV)is an enveloped,non-segmented,and singlestranded RNA virus that belongs to the genus Lyssavirus within the Rhabdoviridae family(Douglas et al.,2013).RABV causes rabies,and although vaccines are available,rabies continues to be a global public health concern causing more than 60,000 human deaths each year(WHO,2013).There is a high prevalence especially in developing countries in Asia and Africa(Hampson et al.,2015;Singh et al.,2017). 展开更多
关键词 al. VACCINE RABIES
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部